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a b s t r a c t
APOBEC3s (A3) are Zn2þ dependent cytidine deaminases with diverse biological functions and
implications for cancer and immunity. Four of the seven human A3s restrict HIV by ‘hypermutating’
the reverse-transcribed viral genomic DNA. HIV Virion Infectivity Factor (Vif) counters this restriction by
targeting A3s to proteasomal degradation. However, there is no apparent correlation between catalytic
activity, Vif binding, and sequence similarity between A3 domains. Our comparative structural analysis
reveals features required for binding Vif and features inﬂuencing polynucleotide deaminase activity in
A3 proteins. All Vif-binding A3s share a negatively charged surface region that includes residues
previously implicated in binding the highly-positively charged Vif. Additionally, catalytically active A3s
share a positively charged groove near the Zn2þ coordinating active site, which may accommodate the
negatively charged polynucleotide substrate. Our ﬁndings suggest surface electrostatics, as well as the
spatial extent of substrate accommodating region, are critical determinants of substrate and Vif binding
across A3 proteins with implications for anti-retroviral and anti-cancer therapeutic design.
& 2014 Published by Elsevier Inc.
Introduction
The APOBEC family of enzymes, present in all primate genomes
(LaRue et al., 2009), has been under positive selective pressure over
33 million years of evolutionary history (Sawyer et al., 2004). This has
given rise to multiple sub-family members through gene duplication
events (LaRue et al., 2008). Located on chromosome 22 in humans,
the APOBEC3 proteins exhibit diverse subcellular localization, tissue
expression patterns and biological functions. The human APOBEC3
family of cytidine deaminase enzymes play diverse biological roles
such as restricting endogenous retroelements (Lovsin and Peterlin,
2009;, Muckenfuss et al., 2006), mitigating HIV-1 infection (Albin and
Harris, 2010; Sheehy et al., 2002), epigenetic regulation (Carpenter
et al., 2012; Guidotti et al., 2013; Guo et al., 2011; Wijesinghe and
Bhagwat, 2012), and repairing double-stranded breaks in cellular
DNA (Nowarski et al., 2012). These enzymes are also strongly asso-
ciated with various cancers (Alexandrov et al., 2013; Burns et al.,
2013a, 2013b; Roberts et al., 2013).
Differences in expression of the various APOBEC3 proteins across
various tissues types are correlated with tissue function (Barbosa-
Desongles et al., 2013; Guidotti et al., 2013; Koning et al., 2009;
Refsland et al., 2010), pathological condition (Burns et al., 2013a,
2013b; Liu et al., 2013; Taylor et al., 2013) or immunological role
(Okeoma et al., 2010; Wang et al., 2007). Cellular compartmentaliza-
tion varies in a similar manner, with the various APOBEC3 proteins
localizing to the cytoplasm (Land et al., 2013; Stenglein et al., 2008;
Vetter and D’Aquila, 2009), forming complexes with RNA (McDougall
and Smith, 2011; Zhang et al., 2008, 2010) and cellular proteins
(Aynaud et al., 2012; Jager et al., 2012a, 2012b), or translocating to the
nucleus (Lackey et al., 2012, 2013; Mussil et al., 2013). Substrate
speciﬁcity, leading to further specialization of these cytidine deami-
nase enzymes, is determined by nucleotides ﬂanking the target
(deoxy/methyl) cytidine (Carpenter et al., 2010; Iwatani et al., 2006;
Rathore et al., 2013; Rausch et al., 2009; Wijesinghe and Bhagwat,
2012) with implications for immunity and epigenetic regulation.
The structural basis underlying the physiological, cellular and
biochemical characteristics mentioned above are not well under-
stood. The human APOBEC3 proteins are comprised of either one
or two domains, subservient to the number of Zn2þ coordinating
sites in the amino acid sequence (Conticello et al., 2005; LaRue
et al., 2008, 2009). The single-domain proteins, APOBEC3A (A3A),
APOBEC3C (A3C) and APOBEC3H (A3H), each have one Zn2þ
coordinating site that is also the enzyme catalytic center. APO-
BEC3B (A3B), APOBEC3D (A3D), APOBEC3F (A3F) and APOBEC3G
(A3G) each contain two Zn2þ coordinating sites located within
nearly equal sized N- and C-terminal domains. The Zn2þ coordi-
nating sites located within the C-terminal domains are known to
be catalytically active in all double-domain proteins. However, the
Zn2þ coordinating sites within the N-terminal domains were
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never unequivocally demonstrated to be deamination capable. The
Zn2þ coordinating sites in each APOBEC3 domain are classiﬁed
based on signature sequence motifs into three domain classes, Z1,
Z2 and Z3 (LaRue et al., 2008). A3A, A3B C-terminal domain (CTD)
and A3G-CTD are Z1 domains. A3C, A3D-CTD, A3F-CTD and the
N-terminal domains (NTD) of all double-domain APOBEC3 pro-
teins are Z2 domains, whereas A3H is the sole member of the Z3
domain class (Fig. 1).
Recent studies have advanced the structural understanding of this
family of proteins by solving NMR and high-resolution crystal
structures of A3G-CTD (Chen et al., 2008; Furukawa et al., 2009;
Harjes et al., 2009; Holden et al., 2008; Shandilya et al., 2010), A3C
(Kitamura et al., 2012), A3F-CTD (Bohn et al., 2013; Siu et al., 2013)
and A3A (Byeon et al., 2013). These structures have elucidated details
of the enzyme active-site region, adjacent putative substrate binding
regions, and structural features that may inﬂuence multimer assem-
bly or binding to other host/non-host proteins. However, no structural
information regarding any of the N-terminal domains of double-
domain enzymes is currently available. These domains have been
characterized to be essential for activity of the full-length proteinwith
well-deﬁned residues that play numerous roles including binding to
polynucleotides, such as single-stranded DNA (ssDNA) or RNA, and
interaction with protein binding partners: The A3B-NTD carries
residues that signal nuclear localization and import (Lackey et al.,
2012). The A3F-NTD & A3G-NTD contribute both to DNA binding as
well as enzymatic processivity (Ara et al., 2014; Chelico et al., 2006)
and contain sequences required not only for binding HIV-1 Vif (that
leads to their proteasomal degradation) (Song et al., 2012; Xu et al.,
2004), but also for packaging into HIV virions (Navarro et al., 2005).
Individual APOBEC3 domains can exhibit differences in subcellular
localization compared to the full-length enzyme; for example either
domain of A3D individually expressed, may localize to the nucleus,
but the full-length protein is cytoplasmic (Lackey et al., 2012).
Thus much remains to be understood of the functional signiﬁcance
of the full-length double domain APOBEC3s.
The structural data on the APOBEC3 domain family enables
detailed analyses of the biophysical characteristics of these enzymes
never previously possible. Attempts at modeling the structures of
some of these A3 domains, based on previously reported structures,
have helped expand our understanding of the structural basis
underlying their functional roles (Aydin et al., 2014; Desimmie et
al., 2014). Structural comparisons can identify putative determi-
nants of substrate orientation in the active-site region and provide
insights into residues inﬂuencing substrate binding, speciﬁcity and
product release. Comparative analysis of surface electrostatic pro-
ﬁles may identify regions that inﬂuence charge-driven interactions
with other proteins or control movement across membranes or
charge gradients, with implications for cellular organelle localiza-
tion, formation of large complexes and packaging into virions. Loop-
lengths may be key in regulation of enzymatic activity by auto-
inhibition, differences in substrate binding, domain assembly,
oligomerization, or conformational plasticity accessible to an APO-
BEC3 protein domain.
In this study, we present a comprehensive structural analysis of
all human APOBEC3 protein domains based on sequence compar-
isons and recently published structures. A sequence similarity
driven and comparative approach using the most appropriate
templates enabled modeling the human APOBEC3 with yet unde-
termined structures. The analysis of structural, biochemical and
biophysical characteristics of human APOBEC3s provides a unique
view of domain properties based on sequence analysis, surface
electrostatic potential and active-site region landscape, supported
with myriad experimental data from current literature. The com-
parative analyses provide insights into structural features that may
inﬂuence substrate binding and catalytic activity, as well as the
ability to bind HIV-1 Vif.
Fig. 1. (A) Schematic representation of domain organization in human APOBEC3 proteins: Each oval represents a domain, with the N-terminal (NTD) and C-terminal (CTD)
domains in double-domain APOBEC3 proteins indicated by a black linker. The domains are colored by Z-domain sequence signature (Z1: green, Z2: orange, Z3: blue) and
indicated as catalytically active by the n symbol. Domains that bind to HIV-1 Vif are indicated by the yellow coloration. (B) Protein sequence homology based phylogram
based on the multiple sequence alignment in (Fig. 2). Branch coloring represents Z-domain signature as in (A) and numbers indicate branch lengths. Domains with solved
structures are highlighted within boxes (yellow). The dashed open bracket (red) indicates the N-terminal domain cluster. (C) Pairwise sequence identity (%) between the
seven target APOBEC3 domains and corresponding template homologs. The target and template domains are colored according to the Z-domain signatures as in (A). Identity
values are colored on a green-to-red scale, from the highest to lowest sequence identity.
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Materials and methods
Sequence analysis
Target sequences were obtained from the NCBI Reference Sequence database
(RefSeq (Pruitt et al., 2007)). Canonical sequences of the template domains from
RefSeq were used for sequence alignment, instead of the actual crystallized
protein’s sequence, as in the case of A3G-CTD (4 mutations and a 4 residue deletion
in 3V4K (Li et al., 2014)) and A3F-CTD (11 mutations in 4IOU (Bohn et al., 2013)).
Multiple sequence alignment was calculated using MUSCLE (Edgar, 2004) with
default parameters, followed by phylogenetic tree analysis using RapidNJ
(Simonsen and Pedersen, 2011) with 10,000 bootstrapped trees. The resulting tree
was visualized and re-rooted with A3H, the most distant sequence, as the root node
using Dendroscope (Huson and Scornavacca, 2012). Needleman–Wunsch pairwise
sequence alignment of all APOBEC3 domains were performed using the program
‘needle’ from the EMBOSS suite (Rice et al., 2000), with parameters gapopen¼10.0
and gapextend¼0.5. The best templates for each target sequence were selected
based on sequence identities, calculated from the pairwise sequence alignments.
Target sequences with pairwise sequence identity greater than 50% to a template
were modeled based solely on that template (A3B-CTD, A3D-CTD and A3B-NTD).
Target sequences with identity less than 50% but greater than 40% were modeled
based on two of the most identical templates (A3D-NTD, A3F-NTD and A3G-NTD).
Only one target sequence (A3H), had no templates with greater than 40% identity
and was modeled based on three most identical templates.
Homology modeling
All template structures (A3A: 2M65 (Byeon et al., 2013); A3C: 3VOW (Kitamura
et al., 2012); A3F-CTD: 4IOU (Bohn et al., 2013); A3G-CTD: 3V4K (Li et al., 2014))
were processed with the ‘Protein preparation Wizard’ in Maestro (2011) (Schrö-
dinger, LLC). Target sequences and corresponding template structures were loaded
in the ‘Multiple Sequence Viewer’ module and used for Knowledge-based homol-
ogy modeling using Prime (Jacobson et al., 2002, 2004). The resulting homology
models were subjected to energy minimization using the Prime ‘Protein Reﬁne-
ment’ module with the OPLS2005 (Banks et al., 2005) force ﬁeld and the
‘automatic’ approach that applies a conjugate gradient method with large gradients
and a truncated Newton method with smaller gradients. Final quality of the models
was estimated from z-DOPE score (Eramian et al., 2008) and the Total PRIME
energy (Banks et al., 2005) (Table 1).
Structural Analysis
Molecular surfaces were calculated within Maestro (Schrödinger, LLC) and
colored with electrostatic potential (ESP) in the range (0.05 to þ0.05 kcal/M) as
red-white-blue, with red being negative ESP, blue positive and white neutral.
SiteMap (Halgren, 2009) was used to identify and evaluate active-site/Zn2þ-
coordinating site volumes, using a ‘Fine’ grid to search around the Zn2þ atom in
the template structures and homology models (pocket volumes reported in
Table 3). Figures were generated using PyMOL (DeLano, 2014).
Results
Sequence and phylogenetic analysis reveal NTDs as a distinct
subgroup
All APOBEC3 proteins/domains share regions of high sequence
similarity as well as speciﬁc residues that are absolutely conserved,
such as the catalytic center residues involved in coordinating zinc as
are revealed by multiple sequence alignment (Fig. 2). Certain regions
are better conserved across speciﬁc subsets of these domains,
indicating a stronger homology amongst a subset. These relation-
ships are best illustrated by a phylogram (Fig. 1B) based on the
multiple sequence alignment, that also reveals a grouping based on
Z-domain signatures (LaRue et al., 2008). The domains with Z2
signature sequences are further subdivided such that all the N-
terminal domains form a distinct subgroup, suggestive of shared
ancestry and structure/function characteristics, as suggested pre-
viously (LaRue et al., 2008).
Pairwise sequence alignments identiﬁed the best template
structures for each of the seven target domain sequences (Fig. 1C).
A3F-CTD and A3C, both Z2 domains, were determined as the best
templates for the ﬁve Z2 targets and used individually or together for
homology modeling (Materials and methods section). Similarly, A3A,
a Z1 domain was identiﬁed as the best template for the only Z1
target, A3B-CTD. All template sequences were less than 35% identical
to A3H, the only Z3 domain protein; therefore, one Z1 (A3G-CTD) and
two Z2 (A3F-CTD, A3C) domain structures were used in combination
as the best available templates. The sequence identity between all
template and target sequence pairs is within range for building the
main chain conformation with reasonable conﬁdence (Chothia and
Lesk, 1986), and is further supported by the absolute sequence
conservation of the Zn2þ coordinating residues across all APOBEC3
domains (Fig. 2).
APOBEC3 domains share a common fold and zinc-coordination
architecture
The template structures, irrespective of the Z-domain signature
or sequence homology, share a common fold comprised of six
α-helices and ﬁve β-strands (Fig. 3A and B). The relative arrange-
ment of secondary structure elements, as demonstrated by the
invariant α-helices, as well as the catalytic Zn2þ-coordinating
residues, one histidine, two cysteines and the catalytic glutamate
residue, follow a similar architecture across all template structures
(Fig. 3D) as well as the homology models (Fig. 4).
However, differences in secondary structure features are corre-
lated with Z-domain signature classes of the template structures
(Fig. 3C). The Z1 domain templates, A3A and A3G-CTD have a
distinct break or ‘kink’ in the β2-strand (Byeon et al., 2013; Harjes
et al., 2009), whereas the Z2 domain structures, A3C and A3F-CTD
have a continuous β2-strand (Fig. 3C). The model of A3B-CTD, a Z1
domain sequence, has a similar ‘kink’ much like the other Z1
domain structures A3G-CTD and A3A (Figs. 3 and 4). This ‘kink’ is
absent in all other models, with the exception of A3G-NTD and
A3H that exhibit a somewhat shorter discontinuous segment in
the β2-strand region compared to the Z1 domain proteins (Fig. 4).
The homologous region in APOBEC2 is continuous, without any
‘kink' or break and based on the arrangement of protein chains in
the APOBEC2 crystal structure. This region was believed to
inﬂuence dimerization (Prochnow et al., 2007), but there is no
direct evidence of a similar role in the case of APOBEC3 proteins.
The role for the varied structure β2-strand region remains elusive,
but perhaps plays a role in differential recognition at a molecular
level amongst the A3 proteins.
Loop lengths also differ across Z-domains, most signiﬁcantly in the
loop 3 region (Figs. 2 and 3), with A3A and A3G-CTD having a longer
loop 3 than A3C or A3F-CTD. The loop 3 of A3G-CTD is involved in
coordinating an intermolecular Zn2þ ion in the A3G-CTD crystal
structure and is a functionally relevant region based on cellular and
biochemical evidence (Li et al., 2014; Shandilya et al., 2010). A3A loop
5 is extended by insertion of two residues (104WG105) between the
two Zn2þ-coordinating cysteine residues (Figs. 2 and 3). This feature,
also observed in the A3B-CTD sequence, is a unique feature of this
Z1-domain sub-branch.
Table 1
The z-DOPE score (Eramian et al., 2008) (as calculated by the Sali Lab ModEVAL
server: http://modbase.compbio.ucsf.edu/modeval/) and Total PRIME energy
(Banks et al., 2005; Maestro, 2011) for the homology models used in this study
(Fig. 4). All numbers rounded-off to one digit after decimal.
A3 domain z-DOPE score Total PRIME energy (kCal/M)
A3B-NTD 2 7.8103
A3B-CTD 0.7 8.1103
A3D-NTD 2.1 9.3103
A3D-CTD 2.2 8.0103
A3F-NTD 2 7.9103
A3G-NTD 2.3 8.1103
A3H 1.3 7.6103
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Surface electrostatics of Vif-interacting regions differ in Vif-binders
and non-binders
Biophysical characteristics, such as surface electrostatic poten-
tial, play an important role in protein-protein interactions. The
isoelectric point (pI) of HIV-Vif, based on amino acid sequence, is
estimated to be around 9.9, implying that Vif is likely highly positively
charged at physiological pH. Similar calculations for the human
APOBEC3 domains reveal a wide range of pI values (Table 2). Surpris-
ingly, there is no apparent correlation between the pI of an APOBEC3
domain and ability to bind Vif (Fig. 1). Vif-binding APOBEC3 domains
include A3C (Kitamura et al., 2012; Smith and Pathak, 2010), A3D-CTD
(Smith and Pathak, 2010), A3F-CTD (Albin and Harris, 2010; Smith
and Pathak, 2010), A3G-NTD (Conticello et al., 2005; Huthoff and
Fig. 2. Multiple sequence alignment of all human APOBEC3 protein domain amino acid sequences. Residues conserved across all proteins are outlined in black with green
highlight. Residues conserved across all, except one, sequence are highlighted in green and not outlined. Residues conserved only in either the C-terminal, or the N-terminal
domain, are highlighted in orange. Zn2þ-coordinating residues are outlined in black with blue highlights and the catalytic Glu residue is highlighted in pink. Secondary
structure elements are indicated as per the A3G-CTD crystal structure (PDB: 3V4K), with α-helices indicated by circles, β-strands by ﬁlled right-handed arrows and loops by
tilde symbols. The β-2/β-20 discontinuity (Fig. 3) is indicated by empty arrows, and loops are numbered by circled numerals.
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Malim, 2007; Russell et al., 2009) and A3H (Hultquist et al., 2011;
Zhen et al., 2010). The HIV-1 Vif interaction generally results in
proteasomal degradation of the corresponding APOBEC3 (Hultquist
et al., 2011; Wiegand et al., 2004; Yu et al., 2003). The pI values of
these domains range from 5.9 (A3G-NTD) to 9.3 (A3D-CTD), indicat-
ing that interaction between Vif and these domains is driven by more
Fig. 3. (A) Schematic representation of the secondary structure elements in APOBEC3 proteins: α-helices are depicted as cylinders (orange), β-strands as large arrows (green)
and loops as curved lines (blue/grey) with encircled numerals indicating the loop-number as in Fig. 2. The β-2/β-20 discontinuity, observed only in the Z1-domain APOBEC3
proteins (A3A, A3G-CTD), is highlighted with a dotted outline and lighter coloration. The Zinc atom is represented as a sphere (dark red), with dashed lines representing the
Zn2þ-coordinating residues, histidine (blue dashes), two cysteines (dark green dashes) and the catalytic glutamate (red dashes), drawn from their respective locations on the
secondary structure. (B): Cartoon representation of A3G-CTD crystal structure (PDB: 3V4K), colored according to the secondary structure schematic in (A). (C): Cartoon
representation of all four structures used as templates. The Z1-domain APOBEC3 proteins show the β-2/ β-20 discontinuity. (D): Ball-and-stick representation of Zinc-
coordinating residues at the active-site region of the template structures. The yellow circle with dashed outline, located just below C291 in A3G-CTD, indicates the position of
A292.
Fig. 4. Cartoon representation of the homology models of human APOBEC3 domains depicting the overall domain architecture and secondary structure features (catalytic
Zn2þ is represented by the dark red spheres).
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nuanced factors than merely the overall charge. Similarly, the calcu-
lated pI values of Vif non-binding domains, including A3A (Jager et al.,
2012a), A3B-NTD (Doehle et al., 2005; Rose et al., 2005), A3B-CTD
(Doehle et al., 2005; Rose et al., 2005), A3D-NTD (Smith and Pathak,
2010; Zhang et al., 2008), A3F-NTD (Rose et al., 2005; Zhang et al.,
2008) and A3G-CTD (Conticello et al., 2005; Schrofelbauer et al., 2004),
exhibit a range from 5.1 (A3B-NTD) to 9.4 (A3G-CTD), suggesting that
overall charge alone is too simplistic and insufﬁcient to explain
the lack of binding. A closer inspection of the surface electrostatic
potentials, when combined with experimental data from published
literature, highlights the stark contrast in charge distribution across
regions that include residues critical for binding Vif as compared to
similar regions in domains that do not bind Vif (Fig. 5) and may help
better comprehend the details of Vif-A3 binding.
Based on surface electrostatic potential, a contiguous, negatively
charged region is identiﬁable in the Vif-binding domains (Fig. 5). The
majority of this region can be traced to include parts of the α-3 and
α-4 helices, loops 6 and 8, and surface accessible regions of the
β-3, β-4 and β-5 sheets, in nearly all these domains. These regions
have been identiﬁed in previous studies by single point mutations
as well as a protein-wide MAPPIT study (Lavens et al., 2010), to
include residues required for interaction with Vif in A3C (Kitamura
et al., 2012; Smith and Pathak, 2010), A3D-CTD (Smith and Pathak,
2010) and A3F-CTD (Albin et al., 2013; Smith and Pathak, 2010). The
primary residue implicated for Vif-binding in the case of A3G-NTD
is D128 (Huthoff and Malim, 2007; Santa-Marta et al., 2005; Xu
et al., 2004), located on loop 7, which is diametrically opposite the
region being discussed (Fig. 5). This apparent discrepancy between
the single-domain A3C and double-domain A3G/F suggests Vif-
binding may be inﬂuenced by inter-domain packaging and oligo-
merization in the double-domain A3G/F. Based on the role played
by oligomerization in double-domain A3 function, for example from
Atomic Force Microscopy (AFM) (Shlyakhtenko et al., 2014, 2011,
2012, 2013) and ﬂuorescence ﬂuctuation spectroscopy (FFS) (Li
et al., 2014), homodimer assembly and/or interactions between
NTD and CTD may help create the surface shape and charge
characteristics that are eventually required to bind Vif. Thus, the
role of individual, binding-critical residues, such as D128 in A3G,
may be exerted not only by the currently accepted direct interac-
tion of Vif-A3G, but also by indirectly inﬂuencing the interaction
interface. Similarly, residue E121 in A3H, a critical determinant for
Vif binding (Zhen et al., 2012), is located on the α-4 helix and close
to loop 7 in the A3H homology model (labeled as K121 in Fig. 5 as
the target A3H sequence used for his study is the isoform 1
(NP_001159475.1) sequence). A3H isoforms that contain K105 and
E121 are known to show stronger anti-viral activity against HIV-1
(Zhen et al., 2010). Even though residues in remote locations are
documented to be critical for binding to Vif, the contiguous,
negatively charged region (Fig. 5) identiﬁed here appears to be a
feature shared amongst Vif-binding A3 domains, and is absent or
interrupted by positively charged patches in the non Vif-binding
domains (Fig. 6). This observation provides additional clues to the
role that surface charge may play in Vif-APOBEC3 interactions, but
further biochemical studies and structural data from Vif-A3 com-
plexes are required for their veriﬁcation.
Table 2
Theoretical isoelectric point (pI) values for the human APOBEC3 domains, based on
the primary amino acid sequence. (Calculated using the Compute pI/MW tool
located at http://web.expasy.org/compute_pi/). Domains known to bind HIV-1 Vif
(Fig. 1) are indicated by an asterisk (n). All numbers rounded-off to one digit after
decimal.
Protein NTD (pI) CTD (pI) Full length (pI)
A3A 6.3
A3B 5.1 8.1 5.9
A3C n 7.5
A3D 7.2 n 9.3 8.7
A3F 5.5 n 8.9 6.9
A3G n 5.9 9.4 8.3
A3H n 9.2
Fig. 5. Electrostatic surface potential (ESP) of the Vif-binding APOBEC3 domains, delineating putative Vif-binding regions in green/white outline. ESP range (0.05 to
þ0.05 kcal/M) as red-white-blue, with red being negative ESP, blue positive and white neutral. All domains oriented as indicated by the cartoon representation of A3F-CTD
crystal structure.
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Surface charge and substrate accommodating pocket volume may
inﬂuence binding afﬁnity and catalytic ability
APOBEC3 proteins are known to bind polynucleotide sequences,
primarily ssDNA, the catalytic substrate (Chelico et al., 2010; Conticello
et al., 2003; Jarmuz et al., 2002; Suspene et al., 2004), as well as
speciﬁc types of RNA (Belanger et al., 2013; Huthoff et al., 2009; Khan
et al., 2007), such as the 7SL RNA (Bach et al., 2008). Binding is a
prerequisite for catalysis of target cytidine(s) on the substrate ssDNA,
which may be inﬂuenced by multiple biophysical factors, including
surface electrostatic potential and the presence or absence of favorable
inter-atomic contacts in the substrate binding regions. To investigate
likely determinants of substrate binding and subsequent catalysis, the
human APOBEC3 domain structures and homology models were
compared with respect to surface electrostatic potential and substrate
accommodating residues that may contribute to favorable interactions
with polynucleotides.
Comparing catalytically active and inactive APOBEC3 domains
revealed differential structural patterns surrounding the potential
substrate binding regions. The catalytically active APOBEC domains,
A3A (Bulliard et al., 2011), A3B-CTD (Bogerd et al., 2007), A3C (Bourara
et al., 2007; Harris et al., 2002), A3D-CTD (Dang et al., 2006), A3F-CTD
(Hache et al., 2005), A3G-CTD (Newman et al., 2005; Shindo et al.,
2003) and A3H (OhAinle et al., 2006), display a deep, well-formed
groove carrying a primarily positive charge on the surface (Fig. 7). The
larger part of this groove, formed by residues from loops 1, 3, 5 and 7,
lies across and spans the active-site pocket, containing the zinc and
the catalytic glutamate residue (Fig. 2, pink highlight; Fig. 3), suggest-
ing a role in accommodating the negatively charged phosphodi-
ester backbone of the substrate ssDNA during substrate binding and
subsequent deamination of the target cytidine. The groove further
extends along the outer surfaces of α-2 and α-3 helices (Figs. 3 and 7),
which although comparatively less positively charged exhibit a similar
shape proﬁle (Fig. 7). Loop 7, which has been implied in DNA motif
recognition, in A3G and A3F (50-CCC-30 vs 50-TC-30 nucleotide
preference), in a number of previous studies (Carpenter et al., 2010;
Holden et al., 2008; Kohli et al., 2009; Siu et al., 2013), forms one of the
boundaries of this groove. The N-terminal domains are catalytically
inactive (with the catalytic capability of A3B-NTD debated (Bogerd
et al., 2007; Hakata and Landau, 2006; Pak et al., 2011)). These inactive
domains reveal comparatively shallower grooves, with A3F-NTD and
A3G-NTD being the most explicit examples (Fig. 8). The groove proﬁle
can be characterized by SiteMap analysis of the active and inactive
domains, which highlights the extent of the pocket that exists around
the Zn2þ-coordinating site. Although the absolute volume (Table 3)
does not directly distinguish the pockets, the shapes of the pockets
are quite distinct (Figs. 7 and 8). With the exception of A3B-NTD,
the pocket volume of a catalytically inactive domain is less than that of
any of the active domains (Table 3). An explanation for A3B-NTD being
the outlier may lie with the seven-residue insertion in the loop 3,
which borders the active-site pocket region and in the absence of
template residues in the A3C structure (Fig. 1), is modeled using
de-novo approach by the homology modeling algorithm, driven
primarily by avoidance of energetically unfavorable clashes, resulting
in a larger pocket than is observed in other NTDs.
The sequence of loop 3, containing N244 in A3G-CTD and
located near the active-site region, also distinguishes active from
inactive domains. Multiple sequence alignment reveals that Asn is
conserved at this position in all active domains, and Gly in all inactive
domains (Fig. 2, outlined, start of loop 3), conﬁrming a role in
substrate recognition and processing, consistent with previous
reports (Bransteitter et al., 2009; Holden et al., 2008). Another con-
served change is linked with A292 in the A3G-CTD (Fig. 2, residue
after the last blue box) that lies near the “ﬂoor” of the active-site
region (Fig. 3), where a bulkier residue is located within inactive
domains. These bulkier side chains appear to result in a shallower
cytidine non-accommodating pocket (Fig. 8). Thus, structural features
combined with sequence comparisons suggest residues 244 and 292
(A3G-CTD numbering) are likely contributory determinants of cata-
lytic activity in APOBEC3 domains.
Fig. 6. Electrostatic surface potential (ESP) of the Vif non-binding APOBEC3 domains, delineating in green/white outline the regions contrasting with Vif-binding domains in
Fig. 5. ESP range (0.05 to þ0.05 kcal/M) as red-white-blue, with red being negative ESP, blue positive and white neutral. All domains oriented identical to the cartoon
representation of A3F-CTD crystal structure in Fig. 5.
S.M.D. Shandilya et al. / Virology 471-473 (2014) 105–116 111
Discussion
This comprehensive computational analysis of all human APOBEC3
proteins provides insights into structural similarities and differences
across this family of domains, which are likely relevant to substrate
binding, catalysis and binding to the HIV-1 protein Vif. Recently
determined structures of some APOBEC3 proteins enabled generating
reliable models of the remaining APOBEC3 domains using the most
homologous domains as templates. Although there have been pre-
vious efforts modeling APOBEC3 protein structures (Albin et al., 2010,
2013; Aydin et al., 2014; Belanger et al., 2013; Bulliard et al., 2009,
2011; Chelico et al., 2006; Chen et al., 2007; Desimmie et al., 2014;
Harjes et al., 2009; Lackey et al., 2012; Lavens et al., 2010; Shirakawa
et al., 2008; Stauch et al., 2009; Stenglein et al., 2008; Zhang et al.,
2008; Zhen et al., 2010, 2012), a comprehensive and comparative
analysis encompassing all human A3 domains has not been reported.
Our analysis focuses on comparing the key characteristics relevant to
the primary biological functions of the APOBEC3s.
The surface electrostatic characteristics common to putative
Vif-binding regions suggest charge complementarity may play a
critical role in Vif interactions of APOBEC3 domains. Vif is an
intrinsically disordered protein with a very high isoelectric point,
and is likely highly positive charged under physiological condi-
tions (Auclair et al., 2007). The contiguous negatively charged
region identiﬁed in Vif-binding APOBEC3 proteins is thus the most
probable determinant driving the interaction with Vif, and corre-
lates well with residues implicated in Vif binding in A3C (Kitamura
et al., 2012) and A3F-CTD (Bohn et al., 2013; Kitamura et al., 2012),
Fig. 7. Upper panel: Electrostatic surface potential (ESP) of catalytically active human APOBEC3 domains, highlighting the putative substrate-binding region around the
Zn2þ-coordinating (active) site. ESP range (0.05 to þ0.05 kcal/M) as red–white–blue, with red being negative ESP, blue positive and white neutral. Lower panel: The
substrate-binding groove/pocket at the active-site region is larger and extends deep into the protein (solid green blobs; Table 3), in catalytically active APOBEC3 proteins; the
protein surface is shown as a dark-blue mesh and secondary structure in cartoon representation. The domain orientation is indicated by the cartoon representation of
A3G-CTD crystal structure with the catalytic Zn2þ atom shown as red sphere, in both panels.
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the two Vif-binding APOBEC3 domains of known structure. More
recently, negative surface charge at the region of α-3 and α-4
helices in A3F was shown to mediate sensitivity to Vif (Land et al.,
2014). Complementing this observation, the published structures
of APOBEC3 domains that do not bind Vif, A3A (Byeon et al., 2013)
and A3G-CTD (Li et al., 2012; Shandilya et al., 2010), have a largely
positive charge distribution across the same regions. The out-
standing exception to this pattern appears in the A3H homology
model, which is overwhelmingly positively charged as per the
calculated electrostatic surface, including near known Vif-binding
residues (K121) in the homologs.
Surface electrostatic potential is also a likely critical factor in
binding the negatively charged ssDNA substrate, as can be observed
in nearly all APOBEC3 domains. Experimental mutagenesis of resi-
dues in and around the active-site region supports the role of
positively charged residues in binding the negatively charged
substrate, as demonstrated speciﬁcally for A3G-CTD, where this
region was also referred to as the Arginine rich “brim-domain”
(Chen et al., 2008; Furukawa et al., 2009; Shindo et al., 2012). Other
studies have shown that introducing negative charge in this region
can abrogate binding to ssDNA, for example, by phosphorylation of
residue T218 (Demorest et al., 2011). Since the primary negative
charge is carried by the phosphodiester backbone in ssDNA, the
presence of substrate (dC) or product (dU) bases in the polynucleo-
tide sequence is less likely to impact this primarily charge-driven
interaction when compared to other biochemical factors like pH.
Surface charge is likely to be strongly inﬂuenced by pH in the local
environment, with implications for ssDNA binding, as reported
recently for A3A (Pham et al., 2013), and thus play a critical role
in enzymatic activity.
Topographical surface charge complementarity may contribute
a signiﬁcant component of the A3 domains’ afﬁnity for positively
charged Vif and negatively charged substrate ssDNA backbone, but
is not sufﬁcient to explain catalytic ability. The deamination
reaction likely requires ﬂipping the substrate cytidine base into
the Zn2þ-coordinating (“active-site”) region, as is observed in the
case of other polynucleotide deaminases; for example the S. aureus
t-RNA adenosine deaminase (TadA), where the substrate base is
ﬂipped out of the stacking arrangement and inserted into the
enzyme active site (Losey et al., 2006). The catalytically inactive
domains may bind to the negatively charged ssDNA backbone
based on general charge complementarity, but may fail to position
the targeted cytidine’s (–NH2) group at the enzymatic center to
trigger the catalytic cascade (Snider et al., 2002). The positioning
of the target base for catalysis would also require sufﬁcient spatial
volume to correctly orient the base at the reaction center and
accommodate adjacent portions of the polynucleotide chain. The
Zn2þ-coordinating region, in the catalytically inactive APOBEC3
domains, appears to have smaller pocket volumes for substrate
binding than the catalytically active domains, as evidenced by the
shallower and narrower grooves in the corresponding region.
A deeper exploration of the role played by pocket depth and
Fig. 8. Left panel: Catalytically inactive human APOBEC3 domains, contrasting the Zn2þ-coordinating region’s electrostatic surface potential (ESP) to the catalytically active
domains in Fig. 7. ESP range (0.05 to þ0.05 kcal/M) as red–white–blue, with red being negative ESP, blue positive and white neutral. Right panel: The pocket/groove around
the Zn2þ-coordinating region is smaller and does not extend deep into the protein (solid green blobs; Table 3), in the catalytically inactive APOBEC3 proteins; the protein
surface is shown as a dark-blue mesh and secondary structure in cartoon representation. The domain orientation is indicated by the cartoon representation of A3G-CTD
crystal structure, as in the corresponding panels of Fig. 7.
Table 3
Pocket/groove volume around the active-site/Zn2þ-coordinating-site in the 11
human APOBEC3 domains (solid green blobs in Figs. 7 and 8) as calculated by
SiteMap (Halgren, 2009; Maestro, 2011) (see Materials and methods section). In the
context of double-domain APOBEC3 proteins, the catalytically active domain
(indicated by *) consistently has a larger pocket volume than the inactive domain.
All numbers rounded-off to one digit after decimal.
A3 Domain Pocket volume (Å3)
A3A * 4.1102
A3B-NTD 3.0102
A3B-CTD * 4.0102
A3C * 2.1102
A3D-NTD 0.7102
A3D-CTD * 2.2102
A3F-NTD 1.0102
A3F-CTD * 1.9102
A3G-NTD 0.6102
A3G-CTD * 3.5102
A3H * 1.6102
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substrate accommodating region by future experiments will help
in understanding the mechanistic basis of this observation and
potential biological signiﬁcance.
The surface charge proﬁles, as well as the substrate accommo-
dating volume around the Zn2þ-coordinating region appear cap-
able of inﬂuencing APOBEC3 binding to Vif as well substrate
ssDNA. However, the same features may also be important in
other roles, such as oligomerization, for instance in the case of
A3G which forms high molecular mass complexes (Chiu et al.,
2005) in the cytoplasm, binding to non-substrate polynucleotides,
such as RNA, and possibly play a role in packaging of these potent
anti-HIV proteins into the virions (Li et al., 2014; Wang et al., 2009;
Zhang et al., 2010). Further details of the functional importance of
these features will emerge as experimental data on various APOBEC3
domains become available from future investigations. Regardless, the
structural features identiﬁed here open the possibility of the design
and development of speciﬁc agents targeting the Vif-APOBEC3
interaction for anti-retroviral effect as well as strategies targeting
the disruption of polynucleotide binding interaction to develop anti-
cancer agents.
The models generated for this study have been deposited at the
“Model Archive”, part of the “Protein Model Portal” (Haas et al.,
2013), and are available for download as PDB format ﬁles.
DOI Link: http://dx.doi.org/10.5452/ma-a4mmi
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